Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15253136 | 0.99 | ADORA2A (0.47) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL29108596 | 0.96 | ADORA3 (0.49) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL16585685 | 0.79 | ADORA3 (0.61) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL29108561 | 0.79 | ADORA3 (0.52) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL15253137 | 0.78 | ADORA3 (0.60) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL4551801 | 0.73 | ADORA2A (0.44) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL26968336 | 0.73 | ADORA3 (0.64) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL26968745 | 0.72 | ADORA3 (0.46) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL7490404 | 0.72 | ADORA2A (0.43) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL24207973 | 0.71 | KCNH3 (0.41) | ADORA3ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020061211-A1 | USE OF HIGHLY-SELECTIVE ADENOSINE 3A RECEPTOR SUBTYPE AGONISTS | SAINT LOUIS UNIVERSITY (US) | 2020-03-26 | — | — | WO | claimed |
| US-20220218712-A1 | TREATMENT OF ALZHEIMER'S DISEASE | SAINT LOUIS UNIVERSITY | 2022-07-14 | — | — | US | disclosed |
| US-20220117985-A1 | TREATMENT OF CHRONIC HEADACHES | UNIVERSITY OF MARYLAND, BALTIMORE | 2022-04-21 | — | — | US | disclosed |
| WO-2020168274-A1 | TREATMENT OF CHRONIC HEADACHES | SAINT LOUIS UNIVERSITY (US) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020061211-A1 | USE OF HIGHLY-SELECTIVE ADENOSINE 3A RECEPTOR SUBTYPE AGONISTS | SAINT LOUIS UNIVERSITY (US) | 2020-03-26 | — | — | WO | disclosed |
| US-20190343860-A1 | HIGHLY SELECTIVE ADENOSINE A3 RECEPTOR SUBTYPE AGONISTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS | SAINT LOUIS UNIVERSITY (US) | 2019-11-14 | — | — | US | disclosed |
| WO-2017189504-A1 | HIGHLY SELECTIVE ADENOSINE A3 RECEPTOR SUBTYPE AGONSISTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS | SAINT LOUIS UNIVERSITY (US) | 2017-11-02 | — | — | WO | disclosed |
| US-20150087613-A1 | Inhibition of Opioid Antinociceptive Tolerance and Withdrawal in Nociceptive Pain Therapy | SAINT LOUIS UNIVERSITY | 2015-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218712-A1 | TREATMENT OF ALZHEIMER'S DISEASE | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885ADORA2A 2/4885ADORA2B 4/4885 |
| US-20190343860-A1 | HIGHLY SELECTIVE ADENOSINE A3 RECEPTOR SUBTYPE AGONISTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS | NLN, HTRA2, TFAM | ADORA3 4/4885ADORA2A 5/4885ADORA2B 20/4885 |
| US-20150087613-A1 | Inhibition of Opioid Antinociceptive Tolerance and Withdrawal in Nociceptive Pain Therapy | OPRL1, OPRK1, OPRD1 | ADORA3 5/4885ADORA2A 47/4885ADORA2B 29/4885 |
| US-20220117985-A1 | TREATMENT OF CHRONIC HEADACHES | ADORA3, ADORA2B, ADORA2A | ADORA3 1/4885ADORA2A 3/4885ADORA2B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.